NEXT Oncology Blog

Your NEXT Option™
March 4, 2023

Oserdu FDA approval for Recurrent Metastatic Hormone Receptor Positive Breast cancer with ESR1 mutations

Featured image for “Oserdu FDA approval for Recurrent Metastatic Hormone Receptor Positive Breast cancer with ESR1 mutations”

Latest

See All
February 14, 2023

Primary Results from the Randomized PHASE II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER 2 Neu- Advanced Brest Cancer Treated with Ribociclib Endocrine Therapy versus Treatment of Physicians Choice Combination Chemotherapy.

Featured image for “Primary Results from the Randomized PHASE II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER 2 Neu- Advanced Brest Cancer Treated with Ribociclib Endocrine Therapy versus Treatment of Physicians Choice Combination Chemotherapy.”
January 31, 2023

Evaluation of the Breast Cancer Index in Premenopausal women with Early Stage HR+ Breast Cancer in the Soft Trial.

Featured image for “Evaluation of the Breast Cancer Index in Premenopausal women with Early Stage HR+ Breast Cancer in the Soft Trial.”
January 9, 2023

Grand Opening of joint venture brings access to proprietary Phase I program to more patients

January 2, 2023

ADCs in Breast Oncology: Present & Future

Featured image for “ADCs in Breast Oncology: Present & Future”

© NEXT Oncology - Your NEXT Option™

2829 Babcock Road Suite 300, San Antonio, Texas 78229

Call Now Button